Dwarakanathan Ranganathan, Saskia Leibowitz, George T John, Michelle A Neller, George R Ambalathingal, Leone Beagley, Archana Panikkar, Shannon Best, Jyothy Raju, Hilary Reddiex, Sharad Ratanjee, Monica Suet Ying Ng, Corey Smith, Rajiv Khanna
{"title":"狼疮肾炎患者的自体 Epstein-Barr 病毒特异性收养 T 细胞疗法。","authors":"Dwarakanathan Ranganathan, Saskia Leibowitz, George T John, Michelle A Neller, George R Ambalathingal, Leone Beagley, Archana Panikkar, Shannon Best, Jyothy Raju, Hilary Reddiex, Sharad Ratanjee, Monica Suet Ying Ng, Corey Smith, Rajiv Khanna","doi":"10.1002/cti2.70015","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Dysregulation of Epstein-Barr virus (EBV)-specific cellular immunity has been hypothesised as one of the contributing factors in the pathogenesis of systemic lupus erythematosus (SLE). Lupus nephritis is a major risk factor for overall morbidity in SLE. Immune-based strategies directed to EBV have been proposed as potential therapeutic strategy for SLE and lupus nephritis.</p><p><strong>Methods: </strong>Autologous EBV latent antigen-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells were expanded <i>in vitro</i> and adoptively transferred to a lupus nephritis patient.</p><p><strong>Results: </strong>This adoptive immunotherapy had no immediate adverse effects, and the patient was subsequently treated with the anti-CD20 antibody, obinutuzumab. The patient showed a reduction in anti-dsDNA antibodies and improved glomerular filtration rate but remained nephrotic. These observations were coincident with a reduction in anti-viral and global T-cell activation.</p><p><strong>Conclusion: </strong>To our knowledge, this is the first report of the use of EBV-specific adoptive immunotherapy to treat a patient with lupus nephritis.</p>","PeriodicalId":152,"journal":{"name":"Clinical & Translational Immunology","volume":"13 11","pages":"e70015"},"PeriodicalIF":4.6000,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11574558/pdf/","citationCount":"0","resultStr":"{\"title\":\"Autologous Epstein-Barr virus-specific adoptive T-cell therapy in a patient with lupus nephritis.\",\"authors\":\"Dwarakanathan Ranganathan, Saskia Leibowitz, George T John, Michelle A Neller, George R Ambalathingal, Leone Beagley, Archana Panikkar, Shannon Best, Jyothy Raju, Hilary Reddiex, Sharad Ratanjee, Monica Suet Ying Ng, Corey Smith, Rajiv Khanna\",\"doi\":\"10.1002/cti2.70015\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>Dysregulation of Epstein-Barr virus (EBV)-specific cellular immunity has been hypothesised as one of the contributing factors in the pathogenesis of systemic lupus erythematosus (SLE). Lupus nephritis is a major risk factor for overall morbidity in SLE. Immune-based strategies directed to EBV have been proposed as potential therapeutic strategy for SLE and lupus nephritis.</p><p><strong>Methods: </strong>Autologous EBV latent antigen-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells were expanded <i>in vitro</i> and adoptively transferred to a lupus nephritis patient.</p><p><strong>Results: </strong>This adoptive immunotherapy had no immediate adverse effects, and the patient was subsequently treated with the anti-CD20 antibody, obinutuzumab. The patient showed a reduction in anti-dsDNA antibodies and improved glomerular filtration rate but remained nephrotic. These observations were coincident with a reduction in anti-viral and global T-cell activation.</p><p><strong>Conclusion: </strong>To our knowledge, this is the first report of the use of EBV-specific adoptive immunotherapy to treat a patient with lupus nephritis.</p>\",\"PeriodicalId\":152,\"journal\":{\"name\":\"Clinical & Translational Immunology\",\"volume\":\"13 11\",\"pages\":\"e70015\"},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2024-11-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11574558/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical & Translational Immunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/cti2.70015\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical & Translational Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/cti2.70015","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的：爱泼斯坦-巴氏病毒（EBV）特异性细胞免疫失调被认为是系统性红斑狼疮（SLE）发病机制的诱因之一。狼疮性肾炎是系统性红斑狼疮总体发病率的主要风险因素。针对EB病毒的免疫策略已被提出作为系统性红斑狼疮和狼疮性肾炎的潜在治疗策略：方法：在体外扩增自体EB病毒潜伏抗原特异性CD4+和CD8+T细胞，并将其收养性转移给狼疮肾炎患者：结果：这种采纳性免疫疗法没有立即产生不良反应，患者随后接受了抗CD20抗体--奥比妥珠单抗的治疗。患者体内的抗dsDNA抗体有所减少，肾小球滤过率也有所改善，但仍然存在肾病。这些观察结果与抗病毒和整体 T 细胞活化的减少相吻合：据我们所知，这是首次报道使用 EBV 特异性免疫疗法治疗狼疮肾炎患者。
Autologous Epstein-Barr virus-specific adoptive T-cell therapy in a patient with lupus nephritis.
Objectives: Dysregulation of Epstein-Barr virus (EBV)-specific cellular immunity has been hypothesised as one of the contributing factors in the pathogenesis of systemic lupus erythematosus (SLE). Lupus nephritis is a major risk factor for overall morbidity in SLE. Immune-based strategies directed to EBV have been proposed as potential therapeutic strategy for SLE and lupus nephritis.
Methods: Autologous EBV latent antigen-specific CD4+ and CD8+ T cells were expanded in vitro and adoptively transferred to a lupus nephritis patient.
Results: This adoptive immunotherapy had no immediate adverse effects, and the patient was subsequently treated with the anti-CD20 antibody, obinutuzumab. The patient showed a reduction in anti-dsDNA antibodies and improved glomerular filtration rate but remained nephrotic. These observations were coincident with a reduction in anti-viral and global T-cell activation.
Conclusion: To our knowledge, this is the first report of the use of EBV-specific adoptive immunotherapy to treat a patient with lupus nephritis.
期刊介绍：
Clinical & Translational Immunology is an open access, fully peer-reviewed journal devoted to publishing cutting-edge advances in biomedical research for scientists and physicians. The Journal covers fields including cancer biology, cardiovascular research, gene therapy, immunology, vaccine development and disease pathogenesis and therapy at the earliest phases of investigation.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
